CN114404379A - 一种瑞巴派特缓释片及其制备方法 - Google Patents
一种瑞巴派特缓释片及其制备方法 Download PDFInfo
- Publication number
- CN114404379A CN114404379A CN202210114071.9A CN202210114071A CN114404379A CN 114404379 A CN114404379 A CN 114404379A CN 202210114071 A CN202210114071 A CN 202210114071A CN 114404379 A CN114404379 A CN 114404379A
- Authority
- CN
- China
- Prior art keywords
- rebamipide
- sustained
- release tablet
- microcrystalline cellulose
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ALLWOAVDORUJLA-UHFFFAOYSA-N Rebamipida Chemical compound C=1C(=O)NC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)C1=CC=C(Cl)C=C1 ALLWOAVDORUJLA-UHFFFAOYSA-N 0.000 title claims abstract description 84
- 229950004535 rebamipide Drugs 0.000 title claims abstract description 84
- 239000007939 sustained release tablet Substances 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000011248 coating agent Substances 0.000 claims abstract description 22
- 238000000576 coating method Methods 0.000 claims abstract description 22
- 239000000314 lubricant Substances 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims abstract description 17
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims abstract description 15
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims abstract description 15
- 238000002156 mixing Methods 0.000 claims abstract description 14
- 239000008187 granular material Substances 0.000 claims abstract description 3
- 239000007888 film coating Substances 0.000 claims description 22
- 238000009501 film coating Methods 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 16
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 16
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 16
- 229960003943 hypromellose Drugs 0.000 claims description 14
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 7
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 7
- 238000005550 wet granulation Methods 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 5
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 claims description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 229940069328 povidone Drugs 0.000 claims description 4
- 239000004408 titanium dioxide Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 208000018556 stomach disease Diseases 0.000 claims description 2
- 229960005196 titanium dioxide Drugs 0.000 claims description 2
- 235000010215 titanium dioxide Nutrition 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims 3
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 239000003826 tablet Substances 0.000 abstract description 18
- 239000003405 delayed action preparation Substances 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 17
- 238000009472 formulation Methods 0.000 description 15
- 238000004090 dissolution Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 230000001186 cumulative effect Effects 0.000 description 7
- 239000002994 raw material Substances 0.000 description 6
- 238000013268 sustained release Methods 0.000 description 6
- 239000012730 sustained-release form Substances 0.000 description 6
- 208000007882 Gastritis Diseases 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 208000008469 Peptic Ulcer Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000011361 granulated particle Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010061164 Gastric mucosal lesion Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 208000023652 chronic gastritis Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 238000009474 hot melt extrusion Methods 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920001169 thermoplastic Polymers 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 102000018386 EGF Family of Proteins Human genes 0.000 description 1
- 108010066486 EGF Family of Proteins Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010017886 Gastroduodenal ulcer Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000010220 ion permeability Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210114071.9A CN114404379B (zh) | 2022-01-29 | 2022-01-29 | 一种瑞巴派特缓释片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210114071.9A CN114404379B (zh) | 2022-01-29 | 2022-01-29 | 一种瑞巴派特缓释片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114404379A true CN114404379A (zh) | 2022-04-29 |
CN114404379B CN114404379B (zh) | 2024-01-26 |
Family
ID=81280050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210114071.9A Active CN114404379B (zh) | 2022-01-29 | 2022-01-29 | 一种瑞巴派特缓释片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114404379B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012148181A2 (ko) * | 2011-04-29 | 2012-11-01 | 한국유나이티드제약 주식회사 | 약물 방출제어용 조성물 |
CN105142637A (zh) * | 2013-04-18 | 2015-12-09 | 三进制药株式会社 | 用于预防或治疗干眼症的含瑞巴派特或其前药的口服药物组合物 |
-
2022
- 2022-01-29 CN CN202210114071.9A patent/CN114404379B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012148181A2 (ko) * | 2011-04-29 | 2012-11-01 | 한국유나이티드제약 주식회사 | 약물 방출제어용 조성물 |
CN105142637A (zh) * | 2013-04-18 | 2015-12-09 | 三进制药株式会社 | 用于预防或治疗干眼症的含瑞巴派特或其前药的口服药物组合物 |
Non-Patent Citations (1)
Title |
---|
方亮: "《药用高分子材料学》", vol. 4, 中国医药科技出版社, pages: 107 * |
Also Published As
Publication number | Publication date |
---|---|
CN114404379B (zh) | 2024-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100098759A1 (en) | Controlled-release preparation containing cilostazol and process for the preparation thereof | |
WO2020249001A1 (zh) | 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 | |
JP2013100334A (ja) | 固体投与形中のテトラサイクリン金属錯体 | |
WO2018127088A1 (en) | Lurasidone solid dispersion and preparation method thereof | |
JP2008504250A (ja) | 胃貯留特性を有する経口用徐放性テジサミル製剤。 | |
TWI784575B (zh) | 一種複合物的藥物組合物及其製備方法 | |
JP2023525202A (ja) | ドロタベリン又はその塩を含む制御放出製剤 | |
US20220288056A1 (en) | Pharmaceutical composition containing nitroxoline, nitroxoline oral solid tablet, preparation method therefor and use thereof | |
SK1752001A3 (en) | Pharmaceutical compositions comprising ibuprofen and domperidone | |
EP2515849A1 (en) | Effervescent tablet and granule formulation comprising cefixime | |
ES2963886T3 (es) | Comprimidos que contienen tamsulosina y solifenacina | |
CN114404379B (zh) | 一种瑞巴派特缓释片及其制备方法 | |
KR101093781B1 (ko) | pH조절제를 함유하는 목시플록사신 고형 조성물 | |
KR102274448B1 (ko) | 레바미피드를 포함하는 단일 매트릭스 정제 형태의 방출-제어형 약학 조성물 및 이의 제조방법 | |
KR101387839B1 (ko) | Ph-의존성 용해도를 갖는 활성 성분의 연장 방출형 제제 | |
EP3764983B1 (en) | A sustained release formulation comprising acemetacin with bimodal in vitro release | |
ES2665868T3 (es) | Comprimido que contiene material compuesto con ciclodextrina | |
KR20150044670A (ko) | 제어방출되는 프로피온산 계열의 약제학적 조성물 | |
CN103570679A (zh) | 达比加群酯葡萄糖酸盐及其制备方法和应用 | |
KR20060130006A (ko) | 경구 서방성 정제 | |
US20230390192A1 (en) | Gastro retentive dosage forms comprising deutetrabenazine | |
WO2023136797A2 (en) | A bilayer tablet composition comprising amorphous dapagliflozin and metformin | |
WO2022225489A1 (en) | A bilayer tablet formulation comprising amorphous dapagliflozin and metformin | |
EP4212150A1 (en) | A bilayer tablet composition comprising amorphous dapagliflozin and metformin | |
TWI732762B (zh) | 口服持續釋放調配物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20221020 Address after: 264003 No. 1167, Gangcheng East Street, Laishan District, Yantai City, Shandong Province Applicant after: Yantai liaoran Biotechnology Co.,Ltd. Address before: 311121 room 1301-1310, building B, Zhengyuan wisdom, No. 359, Shuxin Road, Yuhang District, Hangzhou City, Zhejiang Province Applicant before: Hangzhou Muyuan Biomedical Technology Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230606 Address after: 311121 room 1301-1310, building B, Zhengyuan wisdom, No. 359, Shuxin Road, Yuhang District, Hangzhou City, Zhejiang Province Applicant after: Hangzhou Muyuan Biomedical Technology Co.,Ltd. Address before: 264003 No. 1167, Gangcheng East Street, Laishan District, Yantai City, Shandong Province Applicant before: Yantai liaoran Biotechnology Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |